Posted by John. R. Edwardson on Feb 10th, 2019 // No Comments
Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Svb Leerink lowered their Q1 2019 EPS estimates for Gilead Sciences in a report released on Tuesday, February 5th. Svb Leerink analyst G. Porges now expects that the biopharmaceutical company will post earnings of $1.51 per share for the quarter, down from their previous estimate of $1.66. Svb Leerink also issued estimates for Gilead Sciences’ Q2 2019 earnings at $1.64 EPS, FY2021 earnings at $6.70 EPS and FY2022 earnings at $6.29 EPS. Get Gilead Sciences alerts:
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. Gilead Sciences’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.78 EPS. Several other equities research analysts also recently weighed in on GILD. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday. Raymond James set a $90.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Maxim Group set a $84.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, February 5th. Finally, Wells Fargo & Co cut their price target on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, February 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $86.85.
GILD stock opened at $67.47 on Friday. The company has a current ratio of 3.36, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $87.03 billion, a P/E ratio of 10.97, a PEG ratio of 66.46 and a beta of 1.19. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $82.71.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of Gilead Sciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after purchasing an additional 2,195,948 shares during the period. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares during the period. Vanguard Group Inc boosted its position in shares of Gilead Sciences by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares during the period. Capital Research Global Investors boosted its position in shares of Gilead Sciences by 22.5% in the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after purchasing an additional 12,818,301 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.
In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the transaction, the director now directly owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink . Corporate insiders own 1.16% of the company’s stock.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a dividend yield of 3.73%. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 37.07%.
About Gilead Sciences
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.